TNF-α antagonists for the treatment of Crohn’s disease

Bibliography

• VAN DEVENTER SJH: Tumour necrosis factor and Crohn's disease. Gut (1997) 40:443–448.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of the role of TNF in CD.
   Google Scholar
• KNIGHT DM, HAN T, LE J et al.: Construction and initial characterization of a mouse-human chimeric anti-TNE antibody. Mol. Immunol. (1993) 30:1244342453.
   Web of Science ®Google Scholar
• •Initial report of the structure and characteristics of infliximab. DERKX B, TAMINIAU J, RADEMA S et al.: Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet (1993) 342:173-174. First report of anti-TNF chimeric antibody treatment in a patient with refractory CD. VAN DULLEMAN HM, VAN DEVENTER SJH, HOMMES DW et al.: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (CA2). Gastroenterology (1995) 109:129-135. Open labelled study of CA2 in 10 patients with refractory CD.
   Google Scholar
• TARGAN SR, HANAUER SB, VAN DEVENTER SJH et al.: A short-term study of chimeric monoclonal antibody CA2 to tumor necrosis factor a for Crohn's disease. N Engl. J. Med. ( 1997) 337:1029–1035.
   Google Scholar
• •First multi-centre, placebo-controlled, double-blind clinical trial demonstrating efficacy of CA2 in patients with refrac-tory CD.
   Google Scholar
• PRESENT DH, RUTGEERTS P, TARGAN S. et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. (1999) 340: 1398–1405 .
   Google Scholar
• •Multi-centre, placebo-controlled, randomised trial of Infliximab for patients with fistulising CD.
   Google Scholar
• RUTGEERTS P, D'HAENS G, TARGAN S et al.: Efficacy and safety of retreatrnent with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 117:761–769.
   Google Scholar
• •Efficacy of maintenance therapy with infliximab for patients with CD. CENTOCOR, INC.: Remicade Product Insert. BICKSTON SJ, LICHTENSTEIN GR, ARSENEQU KO et al.: The relationship between Infliximab treatment and lymphoma in Crohn's disease. Gastroenterology (1999) 117:1433–1437.
   Google Scholar
• SANDBORN WJ, HANAUER SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflam. Bowel Dis. (1999) 5:119–133.
   PubMed Web of Science ®Google Scholar
• TARGAN SR: Personal communication regarding review ofcases demonstrating delayed hypersensitivity reactions observed in clinical practice. STACK WA, MANN SD, ROY AJ et al.: Randomised controlled trial of CDP571 antibody to tumor necrosis factor-a in Crohn's disease. Lancet (1997) 349:521-524. First randomised, placebo-controlled, double-blind study of CDP571 in patients with CD. CELLTECH CHIROSCIENCE: Press Release (11 November 1999):
   Google Scholar
• VASILIAUSKAS EA, KAM LY, ABREU-MARTIN MT et al.: An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology (1999) 117:1278–1287.
   PubMed Web of Science ®Google Scholar
• •Initial pilot study showing efficacy of thalidomide treatment in refractory, steroid dependent CD. Exp. Opin. Pharmacother. (2000) 1(4) © Ashley Publications Ltd. All rights reserved.
   Google Scholar
• EHRENPREIS ED, KANE SV, COHEN LB et al.: Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology (1999) 117:1271–1277.
   PubMed Web of Science ®Google Scholar
• •Initial open label trial of thalidomide in patients with refrac-tory CD.
   Google Scholar
• MORELAND LW, MARGOLIES G, HECH LW et al.: Recombinant soluable tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory reheumatoid arthritis. J. Rheumatol. (1996) 23:1849–55.
   PubMed Web of Science ®Google Scholar
• •Double-blind single centre study of the efficacy of recombi-nant human sTNFr fusion protein (p80) in patients with RA.
   Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (;75)-Fc fusion protein. N. Engl. J. Med. (1997) 337:141–147.
   PubMed Web of Science ®Google Scholar
• •Multi-centre, randomised, double-blind, placebo-controlled trial of TNF-r:Fc in patients with RA.
   Google Scholar
• WEINBLATT ME, DREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumore necrosis factor receptor: fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl.J. Med. (1999) 340:253–259.
   PubMed Web of Science ®Google Scholar
• •Randomised, placebo-controlled trial demonstrating increased efficacy of etanercept in combination with MTX therapy in patients with RA.
   Google Scholar
• MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor [alpha] monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. (1998) 41:1552–1563.
   PubMed Web of Science ®Google Scholar
• •Clinical trial showing decreased HACA response in patients receiving concurrent MTX and multiple doses of infliximab versus infliximab alone.
   Google Scholar
• HANAUER SB COHEN RD, BECKER RV et al.: Advances in the management of Crohn's disease: economic and clinical potential of Infliximab. Clin. Ther. (1998) 20:1009–1028.
   Google Scholar
• •Economic assessment of the cost of CD treatment.
   Google Scholar
• HAY JW, HAY AR: Inflammatory bowel disease: costs-of illness. J. Clin. Gastroenterol. (1992) 14:309–317.
   PubMed Web of Science ®Google Scholar
• •Economic assessment of the cost of CD treatment.
   Google Scholar
• Drug Topics Red Book. Medical Economics Co., Inc., Montvale, New Jersey, USA (1999):523–564.
   Google Scholar